路透6月16日 - 制药商Supernus Pharmaceuticals SUPN.O周一表示，它将收购Sage Therapeutics SAGE.O，该公司生产治疗神经系统疾病的药物，交易价值高达7.95亿美元。
Supernus提出以每股8.50美元现金收购Sage Therapeutics的股份，如果达到某些里程碑，每股现金收购价最高可达3.50美元。
Sage Therapeutics 的股票在盘前交易中停牌。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.